Please assess the completion status of the following clinical trial:

Trial Title: Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years old~* Tear film assessment that qualifies in both eyes~* Evidence of meibomian gland dysfunction and dry eye in both eyes~* Willingness to comply with study protocol~Exclusion Criteria:~* Systemic disease condition or medication that causes dry eye~* Use of other treatments for MGD or dry eye~* Ocular surgery, trauma, herpes infection, punctal plug insertion or punctal occlusion within past 3 months~* Active eye infection~* Active eye inflammation or recurrent inflammation within past 3 months~* Moderate to severe allergic conjunctivitis~* Severe eyelid inflammation~* Eyelid abnormality that affects lid function~* Ocular surface abnormality that may compromise corneal integrity~* Pregnant or nursing women~* Participation in another ophthalmic clinical trial within past 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LipiFlow System (Type: EXPERIMENTAL): Treatment with LipiFlow System at randomization in Stage 1 of study
- Warm Compress and Lid Hygiene (Type: ACTIVE_COMPARATOR): Control group receiving warm compress therapy and lid hygiene at randomization in Stage 1 of study and crossover LipiFlow System treatment in Stage 2 of study

Based on this trial design, predict the completion outcome and termination type (if applicable).